newsfilter
← Latest News
Business Wire·

Prevail Therapeutics Announces Pricing of Initial Public Offering

NEW YORK--(BUSINESS WIRE)--Prevail Therapeutics Inc. (Nasdaq: PRVL) (Prevail), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative disorders, today announced the pricing of its initial public offering of 7,353,000 shares of its common stock at a price to the public of $17.00 per share. In addition, Prevail has granted the underwriters a 30-day option to purchase up to an additional 1,102,950 shares of its common stock at the initial public offering price less underwriting discounts and commissions.